Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility

Global pharma major Lupin Limited (Lupin) has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage forms. The EIR was issued post the last inspection of the facility conducted in July 2023. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

"We are pleased to receive the EIR with a VAI status from the U.S. FDA for the recent inspection of our Nagpur Unit-1 facility. This achievement underscores our commitment to quality and compliance and also mirrors our core values, reaffirming our commitment to providing high-quality healthcare solutions to our patients around the world," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 1171.55 as compared to the previous close of Rs. 1133.35. The total number of shares traded during the day was 88399 in over 6186 trades.

The stock hit an intraday high of Rs. 1184.00 and intraday low of 1136.90. The net turnover during the day was Rs. 103097938.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA EIR Nagpur Unit1